Compare TSLX & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TSLX | OGN |
|---|---|---|
| Founded | 2010 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 2011 | 2020 |
| Metric | TSLX | OGN |
|---|---|---|
| Price | $18.54 | $6.22 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 4 |
| Target Price | ★ $21.72 | $11.75 |
| AVG Volume (30 Days) | 1.5M | ★ 3.2M |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | ★ 11.24% | 1.25% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.81 | 0.72 |
| Revenue | N/A | ★ $6,216,000,000.00 |
| Revenue This Year | N/A | $0.42 |
| Revenue Next Year | $1.92 | $1.67 |
| P/E Ratio | $10.08 | ★ $8.85 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $16.99 | $6.18 |
| 52 Week High | $25.17 | $15.85 |
| Indicator | TSLX | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 46.00 | 29.30 |
| Support Level | $16.99 | $6.18 |
| Resistance Level | $22.46 | $7.87 |
| Average True Range (ATR) | 0.57 | 0.20 |
| MACD | 0.12 | -0.03 |
| Stochastic Oscillator | 83.52 | 5.49 |
Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. It partners with companies across a variety of industries and excel at providing creative solutions to companies with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.